Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company ...

Sue Bell was one of the first patients to receive the Alzheimer's drug lecanemab in 2020 as part of the clinical trial. It didn't stop the disease.

Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...

With early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow ...

When people have Alzheimer’s disease, their brains slowly accumulate abnormal clumps of two proteins: amyloid and tau. At ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as ...

A new study found that some medications could have the unintended benefit of reducing dementia risk, while others could increase the risk. A doctor comments on the findings.

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

While Leqembi sales performed well outside the U.S. and Skyclarys is set to grow internationally, Medicare Part D changes will hit its U.S. sales, reducing revenue by about $15–$30 million.